» Articles » PMID: 35669894

Venous Thromboembolism in Cancer Surgery: A Report from the Nationwide Readmissions Database

Overview
Journal Surg Open Sci
Specialty General Surgery
Date 2022 Jun 7
PMID 35669894
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The present study characterized the incidence of venous thromboembolism in a contemporary cohort of surgical oncology patients and its association with index hospitalization and postdischarge outcomes.

Methods: Adults undergoing 7 major thoracic and abdominal cancer resections were identified in the 2016-2019 Nationwide Readmissions Database. Multivariable models stratified by operative subtype were developed to evaluate the association of venous thromboembolism with outcomes of interest.

Results: Of an estimated 436,368 patients, venous thromboembolism was identified in 9,811 (2.2%) patients during index hospitalization. Esophageal (4.1%) and gastric (4.1%) resections exhibited the highest rates of venous thromboembolism, whereas pulmonary resection (1.0%) the lowest. Following adjustment, cancer resection type demonstrated the strongest association with venous thromboembolism development among all factors analyzed (adjusted odds ratio: 3.13, 95% confidence interval: 2.60-3.78). Diagnosis of venous thromboembolism was associated with increased mortality (10.2%, 95% confidence interval: 9.4-11.1 vs 1.7, 95% confidence interval: 1.6-1.7) and prolonged index hospital stay (19.5 days, 95% confidence interval: 19.1-20.0 vs 7.5, 95% confidence interval: 7.4-7.5). Of patients who survived index hospitalization, venous thromboembolism occurrence was associated with increased risk of nonhome discharge (56.4%, 95% confidence interval: 54.7-58.0 vs 14.4, 95% confidence interval: 14.2-14.7) and readmission (30.0%, 95% confidence interval: 28.5-31.1 vs 16.9, 95% confidence interval: 16.7-17.1). Additionally, venous thromboembolism substantially increased index hospitalization ($40,000, 95% confidence interval: $38,000-$42,000) and readmission costs ($3,200, 95% confidence interval: $1,700-$4,700).

Conclusion: Rates of venous thromboembolism remain high in surgical oncology patients, with cancer resection type as a major predictor of venous thromboembolism incidence. Venous thromboembolism was associated with inferior clinical and financial outcomes that extended beyond discharge. These findings underscore the importance of continued vigilance and procedure-specific prophylaxis measures.

Citing Articles

Association of chronic kidney disease with acute clinical outcomes and hospitalization costs of cancer resection.

Sakowitz S, Bakhtiyar S, Mallick S, Vadlakonda A, Oxyzolou I, Ali K PLoS One. 2025; 20(1):e0317085.

PMID: 39854408 PMC: 11760676. DOI: 10.1371/journal.pone.0317085.


Variations in Perioperative Thromboprophylaxis Practices: Do the Guidelines Need a Closer Look?.

Martins R, Christophel E, Poulikidis K, Razi S, Latif M, Luo J Ann Thorac Surg Short Rep. 2025; 2(3):422-426.

PMID: 39790380 PMC: 11708662. DOI: 10.1016/j.atssr.2024.04.014.


Late venous thromboembolism in survivors of adolescent and young adult cancer: A population-based study in California.

Abrahao R, Brunson A, Chubak J, Wernli K, Nichols H, Chao C Thromb Res. 2024; 235:1-7.

PMID: 38244373 PMC: 10989999. DOI: 10.1016/j.thromres.2024.01.002.


Outcomes following major thoracoabdominal cancer resection in adults with congenital heart disease.

Sakowitz S, Bakhtiyar S, Ali K, Mallick S, Williamson C, Benharash P PLoS One. 2024; 19(1):e0295767.

PMID: 38165963 PMC: 10760660. DOI: 10.1371/journal.pone.0295767.


Risk and factors associated with venous thromboembolism following abdominal transplantation.

Sakowitz S, Bakhtiyar S, Verma A, Kronen E, Ali K, Chervu N Surg Open Sci. 2023; 13:18-23.

PMID: 37091740 PMC: 10119681. DOI: 10.1016/j.sopen.2023.03.006.

References
1.
Lim W, Le Gal G, Bates S, Righini M, Haramati L, Lang E . American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018; 2(22):3226-3256. PMC: 6258916. DOI: 10.1182/bloodadvances.2018024828. View

2.
van Walraven C, Austin P, Jennings A, Quan H, Forster A . A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-33. DOI: 10.1097/MLR.0b013e31819432e5. View

3.
Lyman G, Culakova E, Poniewierski M, Kuderer N . Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018; 164 Suppl 1:S112-S118. DOI: 10.1016/j.thromres.2018.01.028. View

4.
Spanknebel K, Conlon K . Advances in the surgical management of pancreatic cancer. Cancer J. 2001; 7(4):312-23. View

5.
Bergqvist D . Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. J Surg Oncol. 2007; 95(2):167-74. DOI: 10.1002/jso.20625. View